INS and metabolic syndrome: A recent study suggested that PPARγ activation may decrease the progression of atherosclerosis and increase insulin sensitivity, and may be a potential therapeutic target for the treatment of various diseases, including type 2 diabetes mellitus and dyslipidemia [70].